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Encouraging data have emerged from adoptive T-cell
therapies in advanced forms of cancer. Anti-tumor
immunity is found in tumor infiltrating lymphocytes as
well as engineered T cells where exogenous expression
of a chimeric antigen receptor (CAR) confers cancer
recognition on the cells. Present adoptive immunother-
apy methods are restricted to the use of autologous
patient T-cells due to the limited persistence of allo-
geneic T cells and the potential for graft versus host dis-
ease (GvHD). The use of autologous patient T cells in
cancer immunotherapy is however limited due to the
fact that this approach is complex and time consuming.
We propose a novel approach to treat B cell malignan-
cies based on the use of genetically modified allogeneic
T cells in conjunction with the conditioning regimen
alemtuzumab. Allogeneic T cells were engineered to
express an anti-CD19 CAR and to no longer express
TCRalpha and CD52, responsible for GVHD and the
sensitivity to alemtuzumab, respectively. The inactiva-
tion of the TCRalpha and CD52 genes in allogeneic T
cells was realized by using TALENTM, a novel class of
sequence-specific nucleases created by the fusion of
transcription activator-like effectors (TALEs) to the cat-
alytic domain of an endonuclease. We have shown that
anti-CD19 CAR+ TCR- CD52- allogeneic T cells did
not respond to TCR stimulation, were resistant to alem-
tuzumab treatment and were able to kill target cells
expressing CD19 in vitro and in vivo.
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